{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:49:00Z","timestamp":1792676940390,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,13]]},"DOI":"10.7759\/cureus.96739","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T10:30:12Z","timestamp":1763029812000},"source":"Crossref","is-referenced-by-count":4,"title":["Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies"],"prefix":"10.7759","author":[{"given":"Syed S","family":"Raza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarshal","family":"Zakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Hashmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saira K","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer X","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al.. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015, 373:11-22. 10.1056\/NEJMoa1411892","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde KM","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011, 377:1341-52. 10.1016\/S0140-6736(11)60205-5","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian CM","year":"2013","unstructured":"Apovian CM, Aronne L, Rubino D, et al.. A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013, 21:935-43. 10.1002\/oby.20309","journal-title":"Obesity (Silver Spring)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002595","article-title":"Treating obesity to optimize women's health outcomes","volume":"32","author":"Rubino D","year":"2025","unstructured":"Rubino D, Schon S. Treating obesity to optimize women's health outcomes. Menopause. 2025, 32:S19-30. 10.1097\/GME.0000000000002595","journal-title":"Menopause"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton S","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, et al.. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023, 389:877-88. 10.1056\/NEJMoa2302392","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff AM","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023, 389:514-26. 10.1056\/NEJMoa2301972","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.1999","article-title":"Legal, safety, and practical considerations of compounded injectable semaglutide","volume":"7","author":"Spitery A","year":"2024","unstructured":"Spitery A, Elder MJ, Farhat N, Mohammad I, Lobkovich A. Legal, safety, and practical considerations of compounded injectable semaglutide. Am Coll Clin Pharm. 2024, 7:941-6. 10.1002\/jac5.1999","journal-title":"Am Coll Clin Pharm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23621","article-title":"Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics","volume":"31","author":"Lingvay I","year":"2023","unstructured":"Lingvay I, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring). 2023, 31:111-22. 10.1002\/oby.23621","journal-title":"Obesity (Silver Spring)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA clinical practice guideline on pharmacological interventions for adults with obesity","volume":"163","author":"Grunvald E","year":"2022","unstructured":"Grunvald E, Shah R, Hernaez R, et al.. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022, 163:1198-225. 10.1053\/j.gastro.2022.08.045","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S95299","article-title":"Off-label drugs for weight management","volume":"10","author":"Hendricks EJ","year":"2017","unstructured":"Hendricks EJ. Off-label drugs for weight management. Diabetes Metab Syndr Obes. 2017, 10:223-34. 10.2147\/DMSO.S95299","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ph16020212","article-title":"Pharmacological treatments and natural biocompounds in weight management","volume":"16","author":"Gasmi A","year":"2023","unstructured":"Gasmi A, Mujawdiya PK, Nehaoua A, et al.. Pharmacological treatments and natural biocompounds in weight management. Pharmaceuticals (Basel). 2023, 16:212. 10.3390\/ph16020212","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2300516","article-title":"Medicare part D coverage of antiobesity medications - challenges and uncertainty ahead","volume":"388","author":"Baig K","year":"2023","unstructured":"Baig K, Dusetzina SB, Kim DD, Leech AA. Medicare part D coverage of antiobesity medications - challenges and uncertainty ahead. N Engl J Med. 2023, 388:961-3. 10.1056\/NEJMp2300516","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.29842","article-title":"Coverage and prior authorization policies for semaglutide and tirzepatide in Medicare part D plans","volume":"8","author":"Liu X","year":"2025","unstructured":"Liu X, Lu CA, Shih YT, Jiang C. Coverage and prior authorization policies for semaglutide and tirzepatide in Medicare part D plans. JAMA Netw Open. 2025, 8:e2529842. 10.1001\/jamanetworkopen.2025.29842","journal-title":"JAMA Netw Open"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.0905","article-title":"Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity","volume":"6","author":"Hwang JH","year":"2025","unstructured":"Hwang JH, Laiteerapong N, Huang ES, Mozaffarian D, Fendrick AM, Kim DD. Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity. JAMA Health Forum. 2025, 6:e250905. 10.1001\/jamahealthforum.2025.0905","journal-title":"JAMA Health Forum"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23973","article-title":"Net prices of new antiobesity medications","volume":"32","author":"Hernandez I","year":"2024","unstructured":"Hernandez I, Sullivan SD. Net prices of new antiobesity medications. Obesity (Silver Spring). 2024, 32:472-5. 10.1002\/oby.23973","journal-title":"Obesity (Silver Spring)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.4258","article-title":"Glucagon-like peptide-1 receptor agonist order fills and out-of-pocket costs by race, ethnicity, and indication","volume":"6","author":"Sarpatwari A","year":"2025","unstructured":"Sarpatwari A, Soto MJ, Ganguli I, Sloan CE, Goss F, Sinaiko AD. Glucagon-like peptide-1 receptor agonist order fills and out-of-pocket costs by race, ethnicity, and indication. JAMA Health Forum. 2025, 6:e254258. 10.1001\/jamahealthforum.2025.4258","journal-title":"JAMA Health Forum"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez PJ","year":"2025","unstructured":"Rodriguez PJ, Zhang V, Gratzl S, et al.. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open. 2025, 8:e2457349. 10.1001\/jamanetworkopen.2024.57349","journal-title":"JAMA Netw Open"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.3073","article-title":"State coverage and reimbursement of antiobesity medications in Medicaid","volume":"331","author":"Liu BY","year":"2024","unstructured":"Liu BY, Rome BN. State coverage and reimbursement of antiobesity medications in Medicaid. JAMA. 2024, 331:1230-2. 10.1001\/jama.2024.3073","journal-title":"JAMA"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/427609-medical-management-of-obesity-a-comprehensive-review-of-food-and-drug-administration-fda-approved-and-investigational-therapies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T10:30:12Z","timestamp":1763029812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/427609-medical-management-of-obesity-a-comprehensive-review-of-food-and-drug-administration-fda-approved-and-investigational-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.96739","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,13]]}}}